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Relative risk* of acute and chronic GVHD based on degree of high-resolution
HLA matching
Factor RR of aGVHD (95% CI) RR of cGVHD
(95% CI) (n¼79)
Grade II-IV
(n¼191)
Grade III-IV
(n¼72)
HLA match**
9-10/10 (n¼69) 1.0 1.0 1.0
6-8/10 (n¼246) 1.1 (0.7-1.8) 1.1 (0.5-2.5) 0.7 (0.3-1.5)
<6/10 (n¼89) 1.1 (0.7-2.0) 1.4 (0.6-3.3) 1.1 (0.1-2.5)
*Adjusted for age, gender match, year of transplant, number of units, CD3,
CD34 dose, ATG use, conditioning, recipient CMV status, prior aGVHD as
appropriate; **High-resolution allele match at HLA-A, -B, -C, -DRB1, and -DQ
loci; RR, relative risk; CI, conﬁdence interval
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Introduction: HLA-mismatched unrelated cord blood
transplantation (UCBT) is feasible and, in retrospective
comparative analyses, allows survival rates similar to con-
ventional unrelated HLA-matched adult-derived grafts. It is
clear that the degree of UCB HLA mismatch in patients has a
negative effect on outcomes with low-resolution HLA typing
at A, B, DR. But the impact of HLA disparity on outcomes with
high-resolution HLA typing HLA-A, -B, -C, -DR is unclear.
Patients and Methods: To determine the impact of HLA
disparity on outcomes after UCBT, We retrospectively
reviewed patients with hematologic malignancies who un-
derwent reduced intensity CBT at Toranomon Hospital from
August 2006 and December 2010 consecutively. Patients who
had prior history of transplantation,were inpoor performance
status (ECOGPS>3), had active bacterial or fungal infections at
the time of conditioning were excluded. The most frequently
used conditioning regimenswereﬂudarabine, alkylating agent
(melphalan or busulfan) with total body irradination (TBI),
tacrolimus plusmycophenolatemofetil for GVHD prophylaxis.
DNAs of 97 pairs were analysed for HLA-A, -B, -C, and -DRB1
basedonHighResolution typing. In these caseshigh resolution
typing was carried out retrospectively.
Results: For HLA-A, -B, -C, and -DR based on high resolution
typing the followingmismatch occurred: nomismatch 2(2%),
one mismatch 5(5%), twomismatch 14(14%), three mismatch
32(33%), four mismatch 28(29%), ﬁve mismatch 14(14%), six
mismatch 2(2%). The number of total nucleated cells and
CD34+ cells were not signiﬁcantly different among them.
The cumulative incidence of neutrophil recovery was
83.5% in this study population. It was higher in HLA-B
matched group than in HLA-B mismatched group ( 94.2% vs.
78.5% up to day 60, p¼0.0044), and in multivariate analysis
HLA-B mismatch was independent predictor of engraftment
(HR, 0.074; 95%CI, 0.0074-0.74; p¼0.026). Among the HLA-A,
-C, -DRB1 mismatches, the negative impact of each single
HLA allele mismatch was not signiﬁcant.
The cumulative incidence of grade II to IV aGVHD in this
study population was 52.6%. In multivariate analysis, HLA-A
mismatch (HR, 10.51; 95%CI, 1.95-56.51; p¼0.0061), and
HLA-B mismatch (HR, 51.59; 95%CI, 1.05-2520.0; p¼0.043)
were signiﬁcantly associated with high incidence of grade II-
IV GVHD.
There were no signiﬁcant difference in the cumulative
incidence of TRM, Relapse Rate and OS in this study.
Conclusion: HLA-B allele mismatch was found to have a
signiﬁcant negative impact on engraftment and II-IV aGVHD.193
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The degree of antigen-level (HLA-A, -B) and allele-level
HLA-DRB1 matching has been correlated with the risk of
acute GVHD (aGVHD) in prior studies of umbilical cord
blood transplantation (UCBT), however no impact of HLA
matching on development of chronic GVHD (cGVHD) has
been reported for 4/6-matched UCBT. To understand the
impact of high-resolution HLA allele matching at -A, -B, -C,
-DRB1 and -DQ loci on GVHD we studied 404 recipients of
single- (n¼129) and double-unit (n¼275, based on the
predominating unit) UCBT from 2000 to 2010. Overall cu-
mulative incidence of grade II-IV aGVHD, grade III-IV
aGVHD, and cGVHD was 47%, 18%, and 20%, respectively. HLA
allele-matched recipients, grouped as 9-10/10 (17%), 6-8/10
(61%), and <6/10 (22%), had a similar cumulative incidence
of grade II-IV (43% vs. 47% vs. 52%, p¼0.5) or grade III-IV
(17% vs. 16% vs. 22%, p¼0.4) aGVHD, respectively. In multi-
variable analysis HLA matching did not inﬂuence grade II-IV
and III-IV aGVHD (all p>0.5) after adjustment for the
number of units, CD3, CD34 dose, age, gender match, con-
ditioning, recipient CMV status, ATG use, and the year of
transplant (Table). Use of ATG was independently associated
with a lower risk of grade II-IV aGVHD (relative risk [RR]¼
0.5, p<0.01). Univariate difference in cumulative incidence
of cGVHD for 9-10/10 (17%), 6-8/10 (17%), and <6/10 (29%)
HLA match was confounded by age (RR¼3.4 for 18 years,
p<0.01) and prior aGVHD (RR¼2.3, p<0.01) in multivariable
analysis adjusted for CD34, CD3 dose, and the number of
cord units. No other factors inﬂuenced cGVHD or modiﬁed
the risk of HLA matching on cGVHD. Similar results were
found in a multivariable analysis for stratiﬁed single- and
double-unit UCBT. We conclude that stringent high-resolu-
tion HLA matching at -A, -B, -C, -DRB1 and -DQ loci does not
inﬂuence the incidence of acute or chronic GVHD among
recipients of UCBT.194
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Although the impact of HLA-A, B, C and DRB1 matching in
unrelated hematopoietic stem cell transplantation (HSCT)
has been well reported, the role of HLA-DPB1 matching for
transplant related immunological events, especially chronic
GVHD (c-GVHD), graft-versus-leukemia (GVL) effect and
their relations has not beenwell elucidated. Accumulation of
large scale unrelated HSCT patient-donor pairs and retro-
spective 6 HLA locus allele data including HLA-DPB1 in Japan
Marrow Donor Program enable us to analyze the effects of
HLA-DPB1 matching.
2177 patients met the following criteria were included: HLA-
A, B, C, DRB1 and DQB1 allele matched unrelated donor,
diagnosis of ALL (N¼738), AML (N¼1040) or CML (N¼399),
non-T cell depleted bone marrow without use of ATG, and
survived more than 100 days after transplantation. 632 pa-
tients were matched for HLA-DPB1 allele, 1181 one allele
mismatched, and 364 two allele mismatched in GVH direc-
tion. Tacrolimus-based regimen was employed in 1158 pa-
tients and cyclosporine-based regimen in 1007.
Myeloablative regimen was conditioned in 1956 patients
and non-myeloablative regimen in 221. Multivariable
competing risk regression analyses were conducted to
evaluate the impact of acute GVHD, chronic GVHD and leu-
kemia relapse after transplantation. Confounders considered
were combinations of patient age (linear), donor age (linear),
risk of leukemia relapse (low and high), GVHD prophylaxis,
preconditioning, sex matching and transplanted year. C-
GVHD was treated as time-dependent covariates.
Hazard risk (HR) of one allele and two alleles mismatch at
HLA-DPB1 locus was 0.70 (95% CI 0.58-0.84) and 0.54 (0.41-
0.71) respectively compared with DPB1match (p<0.001). HR
of limited type c-GVHD (n¼350) and extensive type c-GVHD
(n¼563) were 0.55 (0.42-0.74) and 0.45 (0.36-0.58) respec-
tively (p<0.001) compared with no c-GVHD (n¼1264).
Interaction between these two factors was not signiﬁcant
(HR¼1.25, p¼0.278). HLA-DPB1 mismatch had no impact for
c-GVHD (one allele mismatch HR of 0.98 (0.85-1.14) p¼0.84
and two allele mismatch 1.03 (0.85-1.25) p¼0.73, compared
with HLA-DPB1 match. Therefore, HLA-DPB1 matching and
c-GVHD were an independent factor to induce GVL effect.Although HLA-DPB1 mismatch showed signiﬁcant risk factor
of a-GVHD, a-GVHD showed no signiﬁcant HR for leukemia
relapse (HR of grade 1 a-GVHD (n¼640) 1.11 p¼0.32, grade 2
(n¼596) 0.91 p¼0.45, and grade 3-4 (n¼266) 0.78 p¼0.14
compared with grade 0 (n¼762).
Retrospective analysis of HLA-A, B, C, DRB1 and DQB1
complete match unrelated HSCT elucidated the biological
effect of HLA-DPB1 matching without information biases
at transplantation, showing that GVL effect was induced
by HLA-DPB1 mismatch which was independent of
c-GVHD.195
A Universal Approach to Identify Permissible HLA-
Mismatches in HSCT: Predicted Indirectly Recognizable
HLA Epitopes
Kirsten A. Thus 1, Daniel Furst 2,3, Hanneke van Deutekom4,
Jorg Calis 4, Eric Borst 1, Can Kesmir 4, Jurgen Kuball 5,
Joannis Mytilineos 2,3, Eric Spierings 1. 1 Laboratory for
Translational Immunology, UMC Utrecht, Utrecht, Netherlands;
2 Institute for Clinical Transfusion Medicine and
Immunogenetics Ulm, Ulm, Germany; 3German Red Cross
Blood Transfusion Service Baden Wuerttenberg e Hessen, Ulm,
Germany; 4 Theoretical Biology and Bioinformatics, Utrecht
University, Utrecht, Netherlands; 5 Blood and Marrow
Transplantation Program, University Medical Center Utrecht,
Utrecht, Netherlands
Background: HLA mismatches in hematopoietic stem-cell
transplantation (HSCT) correlate with adverse outcome due
to increased alloreactivity. Identiﬁcation of permissible HLA-
mismatches might be beneﬁcial for donor selection when a
10/10 matched donor cannot be found.
Methods: We developed an algorithm based upon the
concept of indirect recognition of HLA mismatches to iden-
tify permissible mismatches. We subsequently analysed
whether in silico prediction of the numbers of peptides
derived from the recipients’ mismatched-HLAmolecules that
can be presented by donor-recipient shared HLA, designated
as Predicted Indirectly ReCognizable HLA-Epitopes
(PIRCHES), correlate with HSCT outcome.
The numbers of PIRCHES presented on HLA class-I
(PIRCHE-I) and -II (PIRCHE-II) were calculated for 909 re-
cipients of a single HLA mismatched unrelated donor (9/10)
using the high resolution HLA-A, -B, -C, -DRB1 and -DQB1
typings. Recipients were subsequently divided into tertiles
according to their PIRCHE score (PIRCHE-I low: 0-1, mid: 2-
4, high 5-31 and PIRCHE-II low: 0-3, mid 4-13, high 14-79).
The clinical outcome of these groups was evaluated and
compared to a reference patient group transplanted with
completely HLA-A, -B, -C, -DRB1 and -DQB1 matched do-
nors (10/10, n¼1847).
Results: Patients in the low PIRCHE tertiles had a signiﬁ-
cantly lower risk for overall mortality, DFS, TRM, and acute
and chronic GvHD, when compared to patients in the mid
and high tertiles. Moreover, these risk in the low PIRCHE
tertiles were similar to those in 10/10 HLA-matched
transplantations.
Conclusions: In this study, we demonstrate that PIRCHES
correlate with clinical alloreactivity. In particular, patients
presenting low PIRCHE-I have similar clinical outcomes as
patients transplanted with a 10/10 HLA-matched donor. Our
data thus suggest that indirect recognition of mismatched
HLA by T cells is an important mechanism in clinical allor-
eactivity after HLA-mismatched HSCT. Determining the
